Skip to main content

Medmira Inc(MIR-X)
TSX Venture

Today's Change
Delayed Last Update
Day Low0.065
Day High0.065
Open:0.065
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change

Top Stories: Medmira Inc

Select a category then submit the form to load news
Newsfile
Upcoming Meeting Dates - January 26, 2026
ACCESS Newswire
MedMira Reports First Quarter Results FY2026
ACCESS Newswire
MedMira Reports FY2025 Fourth Quarter and Year End Financial Results
ACCESS Newswire
Health Canada Approves MedMira's Reveal(R) Rapid TP Test - Urgent New Tool In The Battle Against Syphilis
ACCESS Newswire
MedMira Announces Launch of Clinical Trial for Its Multiplo(R) TP/HIV Self-Test in Canada
ACCESS Newswire
MedMira Reports Second Quarter Results FY2025
ACCESS Newswire
MedMira Inc. and Lovell Announce Partnership to Increase Access to Reveal(R) G4 HIV-1/2 rapid test for VA, Department of Defense
ACCESS Newswire
MedMira Reports Second Quarter Results FY2025
ACCESS Newswire
MedMira Announces Partnership with MediGroup Physician Services in the United States
ACCESS Newswire
MedMira Announces Exclusive Distribution Agreement with Trimedic Inc. for Canada
ACCESS Newswire
MedMira Receives Investigational Testing Authorizations for Multiplo(R) TP/HIV Self-Test and Non-Professional Use Applications
ACCESS Newswire
MedMira Receives Health Canada Approval for Its Reveal(R) G4 Rapid HIV-1/2 Test for Point-of-Care Use
ACCESS Newswire
MedMira Receives Investigational Testing Authorization for its Multiplo(R) Complete Syphilis (TP/nTP) Antibody Test
ACCESS Newswire
MedMira Reports First Quarter Results FY2025
PR Newswire
TSX Venture Exchange Stock Maintenance Bulletins
PR Newswire
Canadian Investment Regulatory Organization Trade Resumption - MIR
PR Newswire
Canadian Investment Regulatory Organization Trading Halt - MIR
ACCESS Newswire
MedMira receives Health Canada approval for its Multiplo(R) Rapid (TP/HIV) Test for Syphilis and HIV
ACCESS Newswire
MedMira Reports FY2024 Fourth Quarter and Year End Financial Results
ACCESS Newswire
U.S. FDA Approves MedMira's Advanced Reveal G4 Rapid HIV-1/2 Antibody Test
ACCESS Newswire
Progress Update on Securities
ACCESS Newswire
MedMira Reports Third Quarter Results FY2023
ACCESS Newswire
MedMira Reports Second Quarter Results FY2023
ACCESS Newswire
Update on MedMira’s Reveal TP (Syphilis) Clinical Trials in Canada
Business Wire
Maternova and MedMira Enter Distribution Agreement to Market Rapid Diagnostics for HIV, Syphilis and Hepatitis
ACCESS Newswire
MedMira Enters into Partnership with Maternova for USA and Latin America
ACCESS Newswire
MedMira receives CE mark for its VYRA(TM) CoV2Flu Antigen Test
ACCESS Newswire
Point-of-Care Diagnostic for Trichomonas Vaginalis Based on MedMira's RVF Technology(R)
ACCESS Newswire
MedMira Introduces VYRA TriDemic
ACCESS Newswire
MedMira Receives CE Mark for Its VYRA(TM) COVID-19 Antigen Test
Globe Newswire
MedMira Strengthens and Expands Board
Globe Newswire
MedMira Reports Third Quarter Results FY2022

Profile

MedMira Inc is a biotechnology company engaged in the research, development, and manufacturing of rapid diagnostics and technologies. The company operates in one reportable operating segment, rapid diagnostic products and services. Its product line includes HIV, COVID-19, syphilis, Multiplex, Miriad RVF Toolkit, and H. pylori. The company generates revenue from North America, Europe, and other regions, with the majority generated from North America.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.